Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten. Aficamten is a next-in-class cardiac myosin ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Cytokinetics (NASDAQ:CYTK) said EU regulators have validated the market application for its drug aficamten for the treatment ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics' near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Recent label updates for Bristol Myers’ Camzyos should read positively for obstructive hypertrophic cardiomyopathy patients and physicians, as they could lead to greater categor ...

The Food and Drug Administration is expected to decide in late September whether to approve Cytokinetics' first drug, the heart failure medicine aficamten. Brett Pletcher, who in August joined ...

The company has plans to continue the go-to-market goals for aficamten in Germany in 2025. Cytokinetics, Incorporated (NASDAQ:CYTK) also aims to expand commercial readiness activities in Europe ...

Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...